EPHB4 and neoplasm: Subsequently, the PDGF-BB ligand activates PDGFRβ and EPHB4 through direct and indirect mechanisms, leading to the downregulation of Akt and Erk1/2 pathways, which enhance tumor cell survival and proliferation [39, 40].